BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 6402933)

  • 1. The effect of a biodegradable contraceptive capsule (Capronor) containing levonorgestrel on gonadotropin, estrogen, and progesterone levels.
    Ory SJ; Hammond CB; Yancy SG; Hendren RW; Pitt CG
    Am J Obstet Gynecol; 1983 Mar; 145(5):600-5. PubMed ID: 6402933
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ovulatory dysfunction during continuous administration of low-dose levonorgestrel by subdermal implants.
    Faundes A; Brache V; Tejada AS; Cochon L; Alvarez-Sanchez F
    Fertil Steril; 1991 Jul; 56(1):27-31. PubMed ID: 1906017
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative contraceptive efficacy and mechanism of action of the norgestimate-containing triphasic oral contraceptive.
    London RS; Chapdelaine A; Upmalis D; Olson W; Smith J
    Acta Obstet Gynecol Scand Suppl; 1992; 156():9-14. PubMed ID: 1324557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum levels of d-norgestrel, luteinizing hormone, follicle-stimulating hormone, estradiol, and progesterone in women during and following ingestion of combination oral contraceptives containing dl-norgestrel.
    Brenner PF; Mishell DR; Stanczyk FZ; Goebelsmann U
    Am J Obstet Gynecol; 1977 Sep; 129(2):133-40. PubMed ID: 900174
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hormonal consequences of missing the pill during the first two days of three consecutive artificial cycles.
    Landgren BM; Diczfalusy E
    Contraception; 1984 May; 29(5):437-46. PubMed ID: 6430642
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum levels of FSH, LH, estradiol-17 beta and progesterone following the administration of a combined oral contraceptive containing 20 micrograms ethinylestradiol.
    Carlström K; Lunell NO; Zador G
    Gynecol Obstet Invest; 1978; 9(6):304-11. PubMed ID: 754992
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic changes during treatment with two different progestogens.
    Refn H; Kjaer A; Lebech AM; Borggaard B; Schierup L; Bremmelgaard A
    Am J Obstet Gynecol; 1990 Jul; 163(1 Pt 2):374-7. PubMed ID: 2115298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Abnormal endocrine profile among women with confirmed or presumed ovulation during long-term Norplant use.
    Alvarez F; Brache V; Tejada AS; Faúndes A
    Contraception; 1986 Feb; 33(2):111-9. PubMed ID: 3084166
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blood levels of levonorgestrel in women following vaginal placement of contraceptive pills.
    Alvarez F; Faundes A; Johansson E; Coutinho E
    Fertil Steril; 1983 Jul; 40(1):120-3. PubMed ID: 6407876
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suppression of ovarian function by Microgynon 30 in day 1 and day 5 "starters".
    Taylor DR; Anthony FW; Dennis KJ
    Contraception; 1986 May; 33(5):463-71. PubMed ID: 3757512
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of ethinyl estradiol 20 mcg and levonorgestrel 250 mcg on the pituitary-ovarian function during normal tablet-taking and when tablets are missed.
    Nuttall ID; Elstein M; McCafferty E; Seth J; Cameron ED
    Contraception; 1982 Aug; 26(2):121-35. PubMed ID: 6814817
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hormonal consequences of "missing the pill".
    Wang E; Shi S; Cekan SZ; Landgren BM; Diczfalusy E
    Contraception; 1982 Dec; 26(6):545-66. PubMed ID: 6820336
    [No Abstract]   [Full Text] [Related]  

  • 13. Mode of action of dl-norgestrel and ethinylestradiol combination in postcoital contraception. III. Effect of preovulatory administration following the luteinizing hormone surge on ovarian steroidogenesis.
    Ling WY; Wrixon W; Acorn T; Wilson E; Collins J
    Fertil Steril; 1983 Nov; 40(5):631-6. PubMed ID: 6628707
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bleeding and serum d-norgestrel, estradiol and progesterone patterns in women using d-norgestrel subdermal polysiloxane capsules for contraception.
    Moore DE; Roy S; Stanczyk FZ; Mishell DR
    Contraception; 1978 Apr; 17(4):315-28. PubMed ID: 648154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma progesterone levels during long-term treatment with levonorgestrel silastic implants.
    Croxatto HB; Diaz S; Pavez M; Miranda P; Brandeis A
    Acta Endocrinol (Copenh); 1982 Oct; 101(2):307-11. PubMed ID: 6814139
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gonadotropin and estradiol secretion during the week of placebo therapy in oral contraceptive pill users.
    van der Spuy ZM; Sohnius U; Pienaar CA; Schall R
    Contraception; 1990 Dec; 42(6):597-609. PubMed ID: 2128047
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and endocrinologic study of continuous levonorgestrel administration from subcutaneous solid polydimethylsiloxane rods.
    Roy S; Stanczyk F; Mishell DR; Lumkin M; Gentzschein E
    Contraception; 1980 Jun; 21(6):595-615. PubMed ID: 6775868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Norplant implants: the mechanism of contraceptive action.
    Segal SJ; Alvarez-Sanchez F; Brache V; Faundes A; Vilja P; Tuohimaa P
    Fertil Steril; 1991 Aug; 56(2):273-7. PubMed ID: 1906407
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mode of action of dl-norgestrel and ethinylestradiol combination in postcoital contraception. II. Effect of postovulatory administration on ovarian function and endometrium.
    Ling WY; Wrixon W; Zayid I; Acorn T; Popat R; Wilson E
    Fertil Steril; 1983 Mar; 39(3):292-7. PubMed ID: 6402387
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ovarian function during treatment with high ratio levonorgestrel/ethinyl estradiol as oral contraceptives.
    Johansson ED; Elamsson K; Elmestedt U
    Gynecol Obstet Invest; 1982; 14(2):97-105. PubMed ID: 6811379
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.